After starting dapagliflozin, the kidneys produced more aldosterone hormone for a few days, which might help the body retain salt, but this effect didn't last after two weeks.
Scientific Claim
Dapagliflozin treatment was associated with an increase in 24-hour urinary aldosterone excretion by 3.6 μg/day (95% CI: 2.2 to 5.1) after 4 days in patients with type 2 diabetes and preserved kidney function on a standardized sodium intake, but no significant change at 14 days.
Original Statement
“Mean 24-h urinary aldosterone excretion was 14.0 (8.4) μg/24-h at baseline, which was significantly increased at ST (mean change at day 4: 3.6 μg/24-h [2.2, 5.1]; P < 0.001), while no differences were observed at ET (mean change at day 14: 0.8 μg/24-h [−2.4, 3.9]; P = 0.60)”
Evidence Quality Assessment
Claim Status
appropriately stated
Study Design Support
Design supports claim
Appropriate Language Strength
association
Can only show association/correlation
Assessment Explanation
The study design is nonrandomized and lacks a control group, so only association can be inferred. The claim correctly uses 'associated with' to reflect this limitation.